Weinhoff Gregory M 4

What Happened
Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc (CNTA), sold a total of 73,196 ordinary shares (which may be represented by American Depositary Shares) in two open‑market transactions on March 13, 2026, generating approximately $1,927,131 in proceeds. The larger block was 61,253 shares at a weighted-average price of $26.17 (total $1,602,795); the smaller block was 11,943 shares at a weighted-average price of $27.16 (total $324,336). These were dispositions (sales), which are typically routine and not necessarily a signal about company prospects.

Key Details

• Transaction date: March 13, 2026 (filed same day).
• Sales: 61,253 shares @ weighted avg $26.17 (prices ranged $25.75–$26.70). 11,943 shares @ weighted avg $27.16 (prices ranged $26.805–$27.445).
• Total proceeds: ≈ $1,927,131.
• Shares owned after transaction: not disclosed in the provided filing details.
• Notable footnotes: sales were executed under a Rule 10b5-1 trading plan adopted Nov 12, 2025 (F2); ADS representation noted (each ADS currently represents one ordinary share) (F1). Weighted-average prices reported; the filer will provide per‑price breakdowns on request (F3, F4).
• Timeliness: Filing covers the March 13, 2026 transactions and was filed on the same date (no late filing indicated).

Context

• These were open-market sales under a pre-established 10b5-1 plan, a common mechanism insiders use to sell shares on a scheduled or automated basis. Such sales are routine and do not, by themselves, indicate insider sentiment about future company performance.